FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Washington, D.C. 2004)							
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)													
1. Name and Address of Reporting Person *- McCarthy Timothy A.				2. Issuer Name and Ticker or Trading Symbol Bionik Laboratories Corp. [BNKL]						5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
C/O BIONIK, 483 BAY STREET, N105 (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 08/03/2017							X Officer (give title below) Other (specify below) Chief Commercialization Office				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person				
TORONTO, A6 M5G 2C9										_	Form filed by More than One Reporting Person				
(City	y)	(State)	(Zip)			Tab	ole I -	Non-Deri	vative Securitie	es Acquire	ed, Disposed of	f, or Benefi	cially Owned		
(Instr. 3) Date			2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date, if any (Month/Day/Year)		Date, if Co	(Instr. 8)		1. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		O Fo D	wnership orm: irect (D)	Beneficial Ownership
						(A) or (D)			Price		(I		Indirect (I) nstr. 4)	nstr. 4)	
Reminder: I	Report on a s	eparate line for each	class of securities b	peneficia	lly ov	wned direct	ly or	Person in this	s who respor form are not r ntly valid OM	required	to respond u				474 (9-02)
			Table II						sed of, or Bene nvertible secur		wned				
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		Transaction Code Securities (Instr. 8) Acquired Disposed		Securities Acquired (ADisposed of (Instr. 3, 4,	es (Month/ d (A) or d of (D)		ercisable and Date ay/Year)	Underlyi	Title and Amount of Juderlying Securities Instr. 3 and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
				Code	V	(A)	(D)	Date Exercisab	Expiration le Date	Title	Amount or Number of Shares		Transaction(s (Instr. 4)	(I) (Instr. 4)	
Employee Stock Option (Right to Buy)	\$ 0.21	08/03/2017		Α		1,500,000)	(1)	08/03/2024	Commo Stock	on 1,500,000	\$ 0	1,500,000	D	
Employee Stock Option (Right to Buy)	\$ 0.21	08/03/2017		Α		250,000		(2)	08/03/2024	Commo Stock	250,000	\$ 0	250,000	D	
Employee Stock										Commo	an l				

Reporting Owners

B # 0 N /411	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
McCarthy Timothy A. C/O BIONIK, 483 BAY STREET N105 TORONTO, A6 M5G 2C9			Chief Commercialization Office					

Signatures

/s/ Timothy A. McCarthy	08/23/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reporting person was granted a stock option which shall vest equally over a 3 year period commencing one year from the date of grant and in the two subsequent years on the anniversary of the grant date.
- (2) Reporting person was granted a stock option which shall vest upon, and if and only if, the Company achieves no less than \$5.0 million in sales (as provided in the Company's audited Consolidated Statements of Operations and Comprehensive (Loss) Income) for the fiscal year ending March 31, 2019.

(3) Reporting person was granted a stock option which shall vest upon, and if and only if, the Company achieves no less than \$10.0 million in sales (as provided in the Company's audited Consolidated Statements of Operations and Comprehensive (Loss) Income) for the fiscal year ending March 31, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.